Biotechnology AVX,ACR,AVP.......

[Joshuatree]

BOT( spekky DYOR)

Botanix Pharmaceuticals was recently covered by a range of analysts and research notes which highlighted the company’s key investment drivers as well as the unique proposition the company offers to investors.

Banyan Tree Investment Group produced an in-depth research note which detailed how the company’s leading acne product, BTX1503, could unlock significant value and that Botanix
“remains attractively priced in absolute terms relative to its ASX-listed cannabis and pharmaceuticals peers”. Click here to read the full report.

Botanix was also featured in the April edition of The Passionate Investor and Under The Radar. Both reported on the company’s activities and the use of synthetic cannabidiol as the novel drug active, which is preferred by regulators for its pharmaceutical grade quality and purity. Click here for the issue of The Passionate Investor (please refer to page 21) and here for the Under the Radar Report.

Lastly, earlier in March, Argonaut also initiated coverage of Botanix which highlighted that BTX1503 has “the potential to be a ‘game-changing’ treatment for moderate to severe acne”. Click here for the full report.

Botanix also recently conducted a video interview with its Executive Director Matt Callahan where he discussed the company’s commencement of Phase 1a study for BTX1503 and upcoming milestones. Click here to view the video.

For more information about Botanix, please subscribe to the company’s investor updates by emailing achan[@]buchanwe.com.au.

Note: Botanix does not endorse, confirm, or express a view as to the accuracy of, the forecasts or other statements contained in the materials cited above. Botanix should not be taken to make any representation about its future performance by citing those materials

[DarkHorse]

PAA looks interesting - seem to have turned the corner with positive earnings and new CEO after years of delays which have sapped interest...still tiny mcap. Any thoughts - is anyone following?

[Joshuatree]

Will hopefully get alook at it thanks.
Ive posted on MEB somewhere before. Anyway i hold ,and good announcement out confirming 80% accurate in diagnosing PTSD post traumatic stress disorder PDF

"Over 22 army vets committed suicide a day due to PTSD or depression ,mental disorder."

[DarkHorse]

Thanks for bringing MEB to our attention JT, looks very interesting. I found a useful research report: https://www.baillieuholst.com.au/pub...EB_27jun17.pdf
Financials obviously pretty speculative but interesting analysis of the opportunity - particularly comparison of their objective test with alternative screening methods for mental illness.

[Joshuatree]

BOT kicking goals. If one invest s in biotech ones mindset needs oodles of patience
Botanix Completes Successful Phase 1 BTX 1503 Clinical Study
Successful Pilot Study for BTX 1701 Facial Cleanser

[Joshuatree]

VHT don't think I've mentioned this one , been in a while s/p been going down but today whammo up 26% today
Volpara Health Technologies Limited (VHT) develops digital health solutions to enable personalised, high - quality breast cancer screening based on objective measurements of breast density, compression and radiation dose.
Investor Presentation - FY2017 Results Im still in the red.DYOR

[Joshuatree]

Thanks for bringing MEB to our attention JT, looks very interesting. I found a useful research report: https://www.baillieuholst.com.au/pub...EB_27jun17.pdf
Financials obviously pretty speculative but interesting analysis of the opportunity - particularly comparison of their objective test with alternative screening methods for mental illness.

Cheers DH, heres some more. Michael Phelps olympic champion is onboard now too.

https://www.statnews.com/2017/07/21/...nosis-medibio/

https://www.medgadget.com/2017/07/e...ers-interview-jack-cosentino-ceo-medibio.html

[showstring]

CYP - Cynata Therapeutics is looking good at this price level. Feels like it might be ready for some upside.
Few recent independent research reports published with significantly higher share price targets. Potentially significant phase 1 clinical trial news expected towards end of year...

http://cynata.com/category/news/

DYOR

[DarkHorse]

Have been looking at MEB - yet to jump in but obviously depression is a huge area, and with double the diagnostic accuracy of other methods and - so they say - no competitors at present - it certainly looks interesting.
I'd be interested to know what others think (esp contrary views). Here's the script of Alan Kohler's interview with the CEO:
https://hotcopper.com.au/threads/ann...2#.WXcON9J95a0

[Joshuatree]

Medibio announces positive clinical study results